TABLE 2A.
Treatment exposure (PP)
| Group A (N = 225) | Group B (N = 201) | P | |
|---|---|---|---|
| Total number of cycles | 1460 | 1177 | |
| Cycles with delayed schedule | 275 (19%) | 279 (24%) | .51 |
| Because of neutropenia | 76 (28%) | 81 (29%) | |
| Because of leukopenia | 69 (25%) | 72 (26%) | |
| cycles with dose modification | 113 | 129 | .53 |
| Because of neutropenia | 52 (46%) | 64 (50%) | |
| Because of leukopenia | 43 (38%) | 52 (40%) | |
| Relative dose intensity | .48 | ||
| Oxaliplatin (median [%]) | 127.3 (98%) | 118.4 (91%) | |
| S‐1 or capecitabine (median [%]) | 78.4 (98%) | 75.4 (94%) | |
Data are n (％).